Aldose reductase inhibitors: an update

Area of Science:

• Pharmacology and Therapeutics
• Diabetic Complications Research

Background:

• Aldose reductase inhibitors (ARIs) were initially developed to treat complications arising from diabetes mellitus.
• Early ARIs faced challenges with efficacy and toxicity, limiting their widespread clinical application.
• Tolrestat represents a continued area of investigation within the ARI class.

Purpose of the Study:

• To provide an updated overview of research on the aldose reductase inhibitor (ARI) tolrestat.
• To review the biochemical basis and clinical investigations of tolrestat in managing diabetic complications.
• To assess the current status and potential of tolrestat in clinical trials.

Main Methods:

• A comprehensive MEDLINE search was conducted to identify studies on ARIs, including sorbinil, alrestatin, ponalrestat, and tolrestat.
• Inclusion criteria focused on review articles and clinical trials, with all identified tolrestat trials selected due to limited numbers.
• Pharmaceutical manufacturers were contacted for data on ongoing investigations.

Main Results:

• Most early ARIs have not met expectations for treating diabetic complications due to efficacy and toxicity issues.
• Tolrestat has shown small to moderate benefits in patients, particularly improving paresthesia and neuropathy, but not pain.
• Adverse effects associated with tolrestat are generally minor, mainly involving elevated liver enzymes (alanine aminotransferase).

Conclusions:

• Tolrestat is the sole ARI from the initial group still undergoing active clinical trials.
• Current findings for tolrestat in diabetic neuropathy are encouraging but require further validation.
• Additional data from ongoing studies are essential to determine the definitive clinical utility of tolrestat therapy.